Our lab studies mechanisms of lung ischemia-reperfusion injury (IRI), methods to detect IRI, and identifying therapeutic strategies to prevent IRI after lung transplantation. Our studies explore the role of innate immune cells, alveolar epithelial cells, endothelial cells, and pro- or anti-inflammatory mediators. Ongoing research projects are summarized here.
Role of TRPV4 channels. We are studying how calcium uptake by endothelial cells via transient receptor potential vanilloid 4 (TRPV4) channels mediates lung IRI and vascular inflammation. We are also defining a link between purinergic signaling (via ATP release by Panx1) and TRPV4 activation after IR. More >>
In vivo lung perfusion (IVLP). We are developing a novel in vivo lung perfusion (IVLP) method as a targeted therapy to treat severe acute respiratory distress syndrome (ARDS). More >>
Role of Pannexin-1 channels and extracellular ATP. We are studying the role of ATP released by pannexin-1 (Panx1) channels on endothelial cells in vascular inflammation and neutrophil infiltration after lung transplantation. More >>
Ex vivo lung perfusion (EVLP). We are using EVLP as a platform for delivery of pharmacologic therapies to recondition DCD (donation after circulatory death) lungs for successful transplantation. More >>